ATOMO DIAGNOSTICS LIMITED — AGM Information 2022

Oct 26, 2022

ASX Announcement

27 October 2022

==> picture [75 x 73] intentionally omitted <==

2022 Annual General Meeting – MD & CEO’s Address

In accordance with ASX Listing Rule 3.13.3, Atomo Diagnostics Limited ( Atomo ) attaches the Managing Director & CEO’s Address to be delivered at Atomo’s 2022 Annual General Meeting.

For more information, please contact:

John Kelly Atomo Diagnostics john.kelly@atomodiagnostics.com

Phone: +61 401 922 279

This announcement was authorised by the Managing Director & CEO.

Level 1, 3-5 George St Leichhardt NSW 2040

Atomo Diagnostics Limited ACN 142 925 684

Atomo Diagnostics Limited

==> picture [45 x 11] intentionally omitted <==

==> picture [77 x 11] intentionally omitted <==

==> picture [56 x 11] intentionally omitted <==

==> picture [57 x 11] intentionally omitted <==

==> picture [45 x 11] intentionally omitted <==

==> picture [183 x 178] intentionally omitted <==

CEO PRESENTATION - AGM

==> picture [107 x 12] intentionally omitted <==

A ~~TOMO DIAGNOSTICS LIMITED | (ASX: AT1)~~

==> picture [28 x 27] intentionally omitted <==

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRIVATE AND CONFIDENTIAL

~~PRIVATE AND CONFIDENTIAL~~

==> picture [199 x 31] intentionally omitted <==

This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on information available as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision. Reliance should not be placed on the information or opinions contained in this presentation. An investor must not act on the basis of any matter contained in this presentation but should make its own assessment of Atomo as part of its own investigations.

This presentation has been provided for general information purposes only. It does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Atomo, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, neither Atomo, nor any of its officers, directors, employees and agents, nor any other person, accepts any responsibility or liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. This disclaimer also extends to all and any information and opinions contained in, and any

omissions from, any other written or oral communications transmitted or otherwise made available to the recipient in connection with the opportunity outlined in this presentation and no representation or warranty is made in respect of such information.

The information presented in this presentation is subject to change without notice and Atomo does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The cover image is illustrative only.

This presentation may contains certain forward looking statements that are based on Atomo’s beliefs, assumptions and expectations and on information currently available to Atomo management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Atomo to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding present and future business strategies and the business, economic and competitive environment in which they operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Atomo and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

==> picture [28 x 27] intentionally omitted <==

5

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRIVATE AND CONFIDENTIAL

==> picture [260 x 31] intentionally omitted <==

==> picture [160 x 16] intentionally omitted <==

Empowering people to enjoy healthier, more informed lives through fast, accurate point of care testing. VISION	MISSION Re-imagining diagnostics by putting the user point of care experience at the centre of everything we do. Atomo's mission is to ensure equitable and affordable access to accurate diagnoses and a seamless pathway to treatment.	VALUES Impact -Commercialising products that matter to our users Innovation -Fostering creative thinking and solutions Integrity -Ensuring honesty and fairness in all that we do Collaboration -Working as one global team Excellence -Being recognised as experts in the field

==> picture [28 x 27] intentionally omitted <==

6

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRIVATE AND CONFIDENTIAL

==> picture [338 x 31] intentionally omitted <==

AUD	($m)		($m)	(%)
Revenue		12.34	6.72	84%
Cost of sales		(8.09)	(3.30)	(145%)
Gross Profit		4.25	3.42	24%
Gross Margin		34%	51%
Licence and settlementfeeincome		1.65	-	100%
Total revenue		13.99	6.72	108%
Gross Margin (inc lic & fees)		42%	51%
Other income		1.03	0.81	27%
Employee benefits expense		(4.10)	(3.81)	(8%)
Foreignexchanges gains/(losses)		0.09	(0.41)	122%
Researchand development costs		(1.41)	(0.82)	(72%)
Professionalfees expense		(2.33)	(1.79)	(30%)
Otherexpenses		(2.88)	(2.19)	(32%)
Underlying EBITDA		(3.70)	(4.79)	23%

• Strong revenue growth in FY22

==> picture [132 x 12] intentionally omitted <==

----- Start of picture text -----

Annual Sales Revenue ($m)
----- End of picture text -----

==> picture [262 x 142] intentionally omitted <==

----- Start of picture text -----

14.0
12.0
10.0
8.0
6.0
4.0
2.0
0.0
FY19 FY20 FY21 FY22
----- End of picture text -----

• Total customer revenue increased by 108% to $14m

• Cash on hand at end of Q1 FY23: $11.25 million

• OpEx steady (<A$1m per month)

• Underlying EBITDA 23% improvement on FY21

==> picture [28 x 27] intentionally omitted <==

7

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRIVATE AND CONFIDENTIAL

==> picture [98 x 31] intentionally omitted <==

==> picture [317 x 31] intentionally omitted <==

Completion of industralisation of operations to support volume production (Atomo’s second generation blister machine and cassette capacity up to 18 million units per annum)

==> picture [10 x 14] intentionally omitted <==

Successful participation in the local COVID-19 rapid test market with more than $10 million in sales for the year

==> picture [15 x 14] intentionally omitted <==

Set up of Atomo’s business and scale up of commercial engagement in the US, including senior resources joining the company and participation at key conferences

==> picture [15 x 13] intentionally omitted <==

Development of an Atomo integrated swab device to increase the addressable market being actively targeted by the company

==> picture [18 x 14] intentionally omitted <==

Appropriate use of funds to ensure strong balance sheet and sufficient capital to support FY23 activities

==> picture [15 x 14] intentionally omitted <==

==> picture [28 x 27] intentionally omitted <==

8

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRIVATE AND CONFIDENTIAL

==> picture [320 x 31] intentionally omitted <==

==> picture [10 x 14] intentionally omitted <==

==> picture [15 x 14] intentionally omitted <==

==> picture [15 x 14] intentionally omitted <==

==> picture [17 x 14] intentionally omitted <==

==> picture [15 x 14] intentionally omitted <==

==> picture [16 x 14] intentionally omitted <==

A visionary company reimagining consumer focused solutions and delivering best in class usability in the growing point of care testing market

Strong financial position, committed investors, an experienced board & management team and a motivated cohort of professionals in the business

Proven innovators – award winning products, robust patent portfolio and proprietary knowhow successfully applied to address market needs

Validated unique platforms for the OEM market and for Atomo finished products addressing high growth opportunities

Capital spend complete with technology broadly developed and manufacturing base installed, qualified and available to generate significant economic returns

Broad acceptance and rapid growth in decentralised and home-based testing segments, where meeting user expectations of convenience and simplicity is paramount

==> picture [137 x 133] intentionally omitted <==

==> picture [28 x 27] intentionally omitted <==

9

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRIVATE AND CONFIDENTIAL

==> picture [491 x 31] intentionally omitted <==

Atomo brings a level of product engineering excellence, human factors experience, consumer-centric design thinking and product validation rigor previously unseen in the diagnostics industry

Our overriding product marketing requirement for any Atomo program is that our products deliver overwhelming user preference when compared to the incumbent products

“We want our products to make the current market solution seem obsolete”

Users (whether healthcare workers or consumers) should feel that the product has been specifically designed for them, and that the product:

• looks and feels fit for purpose

• removes steps requiring complexity, user judgement or ambiguity

• makes the user feel confident in the process - that everything has happened as intended

• makes the user happy to use the product again and to recommend to others

==> picture [28 x 27] intentionally omitted <==

10

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRIVATE AND CONFIDENTIAL

==> picture [577 x 31] intentionally omitted <==

==> picture [664 x 265] intentionally omitted <==

----- Start of picture text -----

“Super easy quick test, top
All surveyed users found it easy to use and instructions and quickly
said that they would recommend it to implemented”
others.
South Africa, Iyeza Health Self Test User ,Germany, Amazon
“Super Easy, Quick to Use.”
Self Test User, Germany,
Amazon
“Simple to use! I've previously used the free HIV
test, but had difficulty getting enough blood into the
tube, I also had to wait days for my test results.
With this test I only needed a small amount of blood
and got a result in minutes. Brilliant!
I would rather pay for this test in future if it means it
is this easy - Thank you.”
Self Test User ,UK, Feefo
----- End of picture text -----

==> picture [28 x 27] intentionally omitted <==

11

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRIVATE AND CONFIDENTIAL

==> picture [418 x 31] intentionally omitted <==

Atomo platforms offer improved performance and usability in a variety of point of care settings and across an increasing number of sample types

BLOOD

==> picture [332 x 174] intentionally omitted <==

SWAB

==> picture [36 x 37] intentionally omitted <==

==> picture [36 x 36] intentionally omitted <==

==> picture [180 x 164] intentionally omitted <==

Supports a broad range of swabs and multiple test applications (Nasal, nasopharyngeal, throat, STI and other types of swabs)

The device has integrated Atomo’s patented blister technology. The device can automatically deliver a controlled, sample concentrate volume of buffer and sample to the test strip

==> picture [28 x 27] intentionally omitted <==

12

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRIVATE AND CONFIDENTIAL

==> picture [326 x 31] intentionally omitted <==

Atomo has developed and successfully launched the world’s

first integrated, blood-based RDT solutions for professional use and self-test HIV screening:

• With regulatory approvals including CE Mark for Europe,

Australian TGA, and prequalification by the World Health Organisation, the company’s HIV business is growing. Finished product assembly is carried out at the company’s certified facility in South Africa

==> picture [202 x 142] intentionally omitted <==

Atomo has partnered with NG Biotech to manufacture and supply the Pascal platform for use in the Blood Precision hCG Pregnancy Test

We continue to work with NG to support commercial scale up of the Pascal based pregnancy test in markets outside of France and the UK where the test has been initially launched

==> picture [28 x 27] intentionally omitted <==

13

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRIVATE AND CONFIDENTIAL

==> picture [436 x 31] intentionally omitted <==

Quick data capture and upload to cloud

Image Recognition to interpret results

Qualitative and SemiQuantitative results

Atomo’s patented Blood delivery QC algorithm

Video and animation of user steps – multiple languages

Image Recognition to interpret results (less user error)

Qualitative and Semi-Quantitative results

Atomo’s patented Blood delivery QC algorithm

Affordable, accurate and disposable reader platform - LED based

Integrated lancet, blood and buffer delivery (modified Pascal)

Qualitative and SemiQuantitative results

Can be updated to Bluetooth compatible

Supports 20-100 tests in the field

* Fully developed and ready for commercialisation

• ** Proof of concept developed – not fully developed for commercialisation

==> picture [28 x 27] intentionally omitted <==

14

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRIVATE AND CONFIDENTIAL

==> picture [335 x 31] intentionally omitted <==

Infectious Diseases Testing

(HIV, COVID and Others)

OEM Devices

(Devices, components, Iicenses)

Consumer Health

& Wellness

(Retail and emerging telehealth)

==> picture [230 x 102] intentionally omitted <==

Healthcare Distributors

• Viatris, Owen Mumford, Atomo Direct, large US distributors, others

Diagnostics companies suppling finished rapid tests

• Lumos, NG Biotech, leading IVD companies in POC or entering home test markets

• Atomo’s own finished products requirements

Direct to consumer healthcare businesses

• eCommerce and Retail

• Vitamin D, Coeliac, Anemia, Allergy, Thyroid and STI’s

==> picture [28 x 27] intentionally omitted <==

15

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRIVATE AND CONFIDENTIAL

==> picture [597 x 31] intentionally omitted <==

----- Start of picture text -----

HIV
----- End of picture text -----

==> picture [39 x 12] intentionally omitted <==

==> picture [10 x 12] intentionally omitted <==

==> picture [439 x 16] intentionally omitted <==

==> picture [291 x 12] intentionally omitted <==

• Atomo has seen a significant increase in enquiries and interest in new product development alongside increased interest in point of care and home-based testing post pandemic

• Atomo’s executive team have been in the US several times this calendar year to support commercial engagement at conferences and to build awareness for the Atomo solutions available to potential customers.

• We are encouraged by increased interest in home testing post pandemic and the ongoing transition to home based healthcare delivery underway the US and remain confident that our unique solutions will prove attractive to the market as this segment continues to expand in the coming years

==> picture [101 x 12] intentionally omitted <==

• With existing in market products and customers, regulatory approvals and established production demonstrated, Atomo’s products are in a position to establish themselves as the gold standard for rapid testing

• Atomo can offer customers volume cassette supply of finished product using their test strips as part of manufacturing launch and scale up

Inspecting a batch of custom Pascal devices manufactured for a potential new OEM customer seeking to assess performance of their existing test in a self-test compatible format

==> picture [175 x 262] intentionally omitted <==

==> picture [28 x 27] intentionally omitted <==

16

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRIVATE AND CONFIDENTIAL

==> picture [498 x 31] intentionally omitted <==

Over the last 9 months, Atomo has been focusing on development of a go-to-market and partnership strategy involving a number of key elements

• Channel partner feedback on prioritisation of customer demand for at-home self test products, and identifying preferred shortlist

• Progressing discussions on potential channel partner agreements

• Reviewing and finalising industrial partners (assay and manufacturing) to ensure robust supply chain and ability to scale

==> picture [174 x 14] intentionally omitted <==

==> picture [235 x 224] intentionally omitted <==

----- Start of picture text -----

REGULATORY PATH
REQUIREMENTS
CHANNEL STRIP
PARTNER PARTNERS
QUANTIFIED
OPPORTUNITIES
----- End of picture text -----

==> picture [28 x 27] intentionally omitted <==

17

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRIVATE AND CONFIDENTIAL

==> picture [532 x 31] intentionally omitted <==

Switching focus and investment from expansion of installed manufacturing capacity (now complete) to commercial scale up and business development, including focusing on:

• Continued scale up of our HIV business globally

• Expansion of senior commercial resourcing and associated engagement with market and channel partners

• • Attendance at key industry conferences – AACC, Next Gen Dx, Medica and Arab Health

• Refreshed marketing, collateral and increased promotion – website, materials, videos.

• Atomo video: https://www.youtube.com/watch?v=RVA3BBcOUP4&t=23s

Scale up of Atomo’s OEM customer base utilising our proven blood testing platforms, eHealth solutions and in future Atomo’s swab device, across key OEM channels:

• Direct engagement and promotion to diagnostic companies

• Explore adjacent market opportunities, including animal health

• Commercialise a range of new Finished Tests for Home and POC market channels for the US market. Areas of focus incluede:

• Expanding the rollout out of the Pascal based blood-based pregnancy test for home use as well as a screening test in A&E / Emergency

• An App/reader supported semi-Quant test for home monitoring

• A swab-based test utilising the Atomo swab device (once commercialised) – applications of potential interest include COVID / Flu A & B combo plus a number of STI’s

==> picture [168 x 273] intentionally omitted <==

==> picture [28 x 27] intentionally omitted <==

18

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRIVATE AND CONFIDENTIAL